Quality of life after treatment for prostate cancer. Curr Urol Rep. 2003; 4: 185-95.Penson DF, Litwin MS: Quality of life after treatment for prostate cancer. Current Urology Reports 2003, 4: 185–195.Penson DF,
Prostate cancer: Treatment after ADT plus docetaxelChemotherapyHormonal therapiesProstate cancerdoi:10.1038/nrurol.2017.196ThomaClemensNat Rev UrolNature Reviews Urology
Learn how Myriad’s genetic testing can help you and your provider navigate crucial prostate cancer treatment decisions with personalized genetic insights.
Radiotherapy: Secondary malignancies after prostate cancer treatmentNature Reviews Clinical Oncology 7, 249 (2010). doi:10.1038/nrclinonc.2010.59Author: Judd W. MoulThe 5-year follow up ...doi:10.1038/nrclinonc.2010.59MoulJudd W.Nature Reviews Clinical Oncology...
Among men, prostate cancer is the major cancer of the reproductive system and it develops at older ages, with most deaths occurring after age 70. daccess-ods.un.org 在男子中,前列腺 癌是主要的生殖系统癌症,会在 年纪较大时发病,大多数死亡是在 70 岁以后, 因为此癌通常增长缓慢,不再建议进行...
Treatment guidelines recommend that curative radiation treatment of prostate cancer be offered only to men whose life expectancy is greater than 10 years. The average life expectancy of North American males is less than 10 years after age 75, yet many me
The largest study of its kind reports that active monitoring for prostate cancer has the same high survival rates after 15 years as radiotherapy or surgery. Men on active monitoring were more likely to see the cancer progress or spread than those receiving radiotherapy or surgery, but ...
BackgroundThe 2 primary therapeutic interventions for localized prostate cancer are delivered by different types of physicians, urologists, and radiation
Currently, digital rectal examination (DRE) and prostate specific antigen (PSA) are used for prostate cancer detection. The American Urological Association recommends that healthy men ages 55-70 should have prostate cancer screening with a DRE and PSA test every two years. Men with risk factors su...
Financial toxicity is a broad term to describe the economic consequences and subjective burden resulting from a cancer diagnosis and treatment. As financial toxicity is associated with poor disease outcomes, recognition of this problem and calls for stra